原创: Research医药Dan Research医药Drug 6月29日
POSTER:
2018年的Global Hepatitis Summit ,发布了Preclinical in‐vivo characterization of an oral TLR7 agonist, AL‐034 (or TQ‐A3334)报告。处在临床开发阶段用于治疗慢性乙型肝炎(CHB)的口服Toll样受体7(TLR7)激动剂JNJ-4964(AL-034 / TQ-A3334)可能在恢复对HBV的免疫应答中起重要作用。(P1‐015: Oral administration of JNJ‐4964 (AL‐034/TQ‐A3334), a selective toll‐like receptor 7 agonist, in AAV/HBV mice for 12 weeks, resulted in potent and sustained anti‐HBV activity with HBsAg seroconversion and detectable HBsAg‐specific T cells and B cells)
2017年的AASLD,天晴和强生也发布了相关数据:AL-034 (or TQ-A3334), a Selective Toll-likeReceptor 7 Agonists for the Oral Treatment ofChronic Hepatitis B Virus Infection。
临床试验:
在国内已经开启一期临床:
Evaluation of Phase Ia Clinical Trial of TQ-A3334 Single-Center, Randomized, Double-Blind, Placebo-Controlled Multi-Dose, Single-Dose, Multiple-Dosed Tolerance, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects。
Registration number:
ChiCTR1800015418
Date of Registration:
2018-03-29
Applicant's institution:
The First Hospital of Jilin University
国外也在一期:
A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-human Study of Orally Administered AL 034 to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses Including Food Effect Evaluation (Part 1) and After Multiple Ascending Doses (Part 2) in Healthy Adult Subjects